Table 1 Clinical Characteristics of CHD Patients and Healthy controls
Parameters | CHD (n = 155) | Controls (n = 175) | Statistics | P value |
|---|---|---|---|---|
Male/Female | 83/72 | 88/87 | χ2 = 0.350 | 0.554 |
Age, y | 60.00 (59.00, 75.00) | 62.00 (53.00, 68.00) | Z = −1.013 | 0.311 |
BMI, kg/m2 | 24.20 ± 2.73 | 22.44 ± 2.88 | t = 5.632 | < 0.001 |
ALT, U/L | 19.21 (14.57, 33.40) | 17.96 (12.57, 24.20) | Z = −2.239 | 0.025 |
AST, U/L | 22.45 (16.70, 37.78) | 20.78 (17.60, 24.35) | Z = −1.924 | 0.054 |
GGT, U/L | 23.75 (17.09, 36.74) | 19.91 (15.24, 29.92) | Z = −2.117 | 0.034 |
ALP, U/L | 83.84 (66.72, 109.08) | 69.71 (57.27, 83.63) | Z = −1.083 | 0.279 |
TG, mmol/L | 1.23 (0.90, 1.61) | 1.12 (0.86, 1.62) | Z = −3.026 | 0.002 |
TC, mmol/L | 4.19 (3.71, 5.13) | 4.64 (3.66, 5.18) | Z = −1.525 | 0.127 |
HDL, mmol/L | 1.00 (0.85, 1.20) | 1.31 (1.05, 1.47) | Z = −7.493 | < 0.001 |
LDL, mmol/L | 2.49 (2.06, 3.18) | 3.01 (2.61, 3.56) | Z = −3.552 | < 0.001 |
TBIL, μmol/L | 13.50 (10.60, 17.96) | 12.10 (9.50, 15.10) | Z = − 0.366 | 0.714 |
FPG, mmol/L | 5.02 (4.49, 6.02) | 4.54 (4.06, 5.05) | Z = −5.879 | < 0.001 |
pharmacological history | lipid-lowering drug | / | Â | Â |